Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | TP53 | P04637 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12774107 | 0.84 | SMN1; SMN2 (0.60) | SMN1; SMN2TP53ALDH1A1KDM4EPOLB | |
| SCHEMBL5231802 | 0.84 | SMN1; SMN2 (0.68) | SMN1; SMN2TP53ALDH1A1POLBHTT | |
| SCHEMBL25755511 | 0.83 | KDM4E (0.53) | SMN1; SMN2TP53ALDH1A1KDM4EALOX15 | |
| SCHEMBL1174392 | 0.80 | — | — | |
| SCHEMBL4489670 | 0.80 | SMN1; SMN2 (0.65) | SMN1; SMN2TP53ALDH1A1KDM4ETSHR | |
| SCHEMBL25031545 | 0.78 | KCNA3 (0.46) | SMN1; SMN2TP53KMT2AL3MBTL1 | |
| SCHEMBL7316521 | 0.77 | SMN1; SMN2 (0.41) | SMN1; SMN2TP53ALDH1A1KDM4ETSHR | |
| SCHEMBL24911581 | 0.77 | SMN1; SMN2 (0.48) | SMN1; SMN2TP53ALDH1A1KDM4ETSHR | |
| SCHEMBL30683693 | 0.76 | SMN1; SMN2 (0.48) | SMN1; SMN2TP53ALDH1A1KDM4ETSHR | |
| SCHEMBL1725970 | 0.76 | SMN1; SMN2 (0.61) | SMN1; SMN2TP53ALDH1A1KDM4ETSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230210999-A1 | TARGETED PROTEASE DEGRADATION (TED) PLATFORM | EUBULUS BIOTHERAPEUTICS (HONG KONG) LIMITED (HK) | 2023-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230210999-A1 | TARGETED PROTEASE DEGRADATION (TED) PLATFORM | UCHL3, UBE2L3, ADAM33 | SMN1; SMN2 2462/4885TP53 449/4885ALDH1A1 2539/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.